Department of
Targeted-therapy
📢 Important Update: Submit Your Manuscript on RTK signaling!
Dear Researchers,
We are thrilled to announce our upcoming Special Issue, "Recent Advances of Receptor Tyrosine Kinases in Solid Tumors," dedicated to shedding light on the vital role of new therapies targeting Receptor Tyrosine Kinases (RTKs) and their downstream signaling in the realm of solid tumors. We are extending the submission deadline in our Special Issue in Biomedicines (IF= 4.7; Q1 journal in Pharmacology and Pharmacy) to February 29, 2024.
Research Spotlight
Triple-negative breast cancer (TNBC) is challenging, making up 15–20% of all breast cancer cases. This study examined how certain drugs, like lapatinib (a dual tyrosine kinase inhibitor targeting EGFR and Her2) and berberine (a plant-based compound), affect TNBC cells. We found that lapatinib activates a protein called Akt in MDA-MB231 TNBC cells, which could contribute to the cancer's resistance to treatment. We also studied the genetic profiles of different TNBC cell lines and patients. Interestingly, lapatinib and berberine enhanced Akt activity in TNBC cells, making them more resistant to treatment. These findings suggest that these drugs may not be effective in treating TNBC and could even make the cancer more resistant to therapy.
Our recent research analyzed the gene expression of specific cancer-promoting proteins in ten different triple-negative breast cancer (TNBC) cell lines and TNBC patients, utilizing GEO and TCGA databases. Our current findings have highlighted that the majority of the chosen cell lines, including MDA-MB231 and TNBC patients, exhibit decreased levels of AKT1, PIK3CA, PTEN, and EGFR genes while showing increased levels of KRAS and DNMTs. These observations suggest that these genes are associated with the invasive nature of TNBC.
🔬 Calling All Young Researchers in Cancer Research! Join the Targeted-Therapy Subgroups and Shape the Future of Solid Tumor Treatment! 🌟
Are you a passionate young researcher with a burning desire to make a difference in the world of cancer research? 🦸♂️🦸♀️
At the Cancer Discovery Network, we're on a mission to unlock the full potential of targeted therapy against solid tumors, with a special focus on breast cancer. 💪🩺
We believe that collaboration and innovation are the keys to breakthroughs, and that's where you come in! We're excited to introduce our new initiative: the Targeted-Therapy Subgroups. 🎯
Here's how you can get involved:
1️⃣ Collaborate: Join a diverse and dynamic community of researchers dedicated to advancing targeted therapy.
2️⃣ Ideate: Share your innovative ideas, and let's brainstorm the next generation of treatment strategies.
3️⃣ Research: Dive deep into the world of solid tumors, especially breast cancer, and explore novel approaches.
4️⃣ Network: Connect with like-minded individuals, mentors, and experts in the field.
5️⃣ Impact: Be part of groundbreaking research that has the potential to transform cancer treatment.
We're looking for enthusiastic individuals who are ready to roll up their sleeves and tackle the challenges of cancer head-on. Whether you're a seasoned researcher or just starting your journey, your unique perspective and ideas are invaluable. 🧬🔍
Join us in the fight against cancer, and let's work together to bring hope, healing, and innovation to patients worldwide. 💗
Interested? Reach out to us today, and let's embark on this exciting journey of discovery and progress. 🚀
c-MET Discovery Subgroup
The c-MET Discovery Subgroup focuses on studying a protein called c-MET, which is super important in cancer. They want to understand how c-MET affects how cancer cells resist treatments like targeted therapies and immunotherapies. They've found that c-MET plays a big role in making the tumor environment friendly to cancer cells by helping them hide from the immune system.
Their research shows that when c-MET is too active, it's linked to a protein called PD-L1, which cancer cells use to protect themselves from the immune system. Also, c-MET seems to change some immune cells from fighting cancer to supporting it, and it helps create more immune cells that suppress the immune response in the tumor.
The subgroup is exploring exciting possibilities. They've been looking at a special antibody called amivantamab, which can target two things: c-MET and EGFR. This antibody seems to help the immune system fight cancer better. This discovery opens doors to new treatments that use both c-MET blocking and immunotherapy, like a double attack against cancer growth and immune suppression.
All in all, this subgroup's research is crucial. It helps us understand how c-MET works in cancer, giving hope for better treatments tailored to each patient. Their dedication to uncovering the mysteries of c-MET in cancer is vital for finding new ways to fight this disease.
Plant-based Drug Discovery Subgroup
🌿 Unlocking the Power of Nature in the Fight Against Cancer 🌿
Are you passionate about exploring the untapped potential of plant-based anticancer drugs? 🌱 Do you believe in the healing properties of nature's pharmacy? 🌼 Join our Natural-Based Anticancer Pharmacology Subgroup and be part of a groundbreaking journey!
Why Plant-Based Anticancer Drugs Matter:
- Nature has provided us with a treasure trove of compounds that have shown remarkable anticancer properties.
- Plant-based drugs offer a promising avenue for developing effective and less toxic cancer treatments.
Research in this field has the potential to revolutionize cancer therapy and improve patient outcomes.
What We Do:
- Explore the vast world of natural compounds and their anticancer potential.
- Investigate the mechanisms of action behind these plant-based drugs.
- Collaborate with experts, researchers, and students who share a passion for natural-based anticancer pharmacology.
- Contribute to the development of safer and more accessible cancer treatments.
Why Join Us:
- Gain valuable insights and expertise in the field of natural-based anticancer pharmacology.
- Collaborate on exciting research projects with real-world applications.
- Connect with a vibrant community of like-minded individuals dedicated to advancing cancer research.
- Make a meaningful impact on the future of cancer treatment and drug development.
Let's Harness the Healing Power of Nature Together! 🌿
Join us in our mission to unlock the full potential of plant-based anticancer drugs. Together, we can make a difference in the lives of cancer patients and bring hope for a healthier future. 🌟
Ready to be a part of this transformative journey? Click the "Join Us" button and become a member of our Natural-Based Anticancer Pharmacology Subgroup today! 🌼🔬🧪